Town Hall on NIH-organized Trials of Antithrombotic Agents in Patients with COVID-19: Hear the Latest and Become Involved in ACTIV-4
Results of robust clinical trials are needed to inform management of and prevent coagulopathies in people with COVID-19. Such studies have been organized within the National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions (ACTIV) program. The ACTIV-4 master protocol will evaluate the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Currently there are three adaptive platform clinical trials within ACTIV-4 that aim to prevent, treat, and address COVID-19-associated coagulopathy (CAC), or clotting, as well as help understand the effects of CAC across three patient populations: inpatient, outpatient, and convalescent. The adaptive nature of the platform will allow a seamless transition to studies that will test multi-regimen anticoagulation approaches. On this webinar, a leader of the three ACTIV-4 studies will review the goal of the study and the research protocol as well as discuss how sites can become involved in the study. The leaders will also address how the studies intersect with each other as well as other ongoing trials in COVID-19 coagulopathies.
Moderator: Lisa M. Baumann Kreuziger, MD, Versiti and Medical College of Wisconsin
W. Keith Hoots, MD; Director, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health
Jeffrey Berger, MD; Co-Principal Investigator, ACTIV-4A; NYU Langone Health
Jean M. Connors, MD; Principal Investigator, ACTIV-4B; Brigham and Women’s Hospital
Thomas L. Ortel, MD, PhD; Study Chair, ACTIV-4C; Duke University Medical Center